The list of compensated medicines is to be completed with a new preparation meant for people with type-II diabetes and heart failure. The cost of the medicine will be compensated at the level of 50% from mandatory health insurances accounts (AOAM).
According to the Health Ministry, the decision has been recently taken by the council for medicines compensated from the AOAM accounts.
The new medicine (Dapagliflozinum) belongs to a class of preparations, which contain specific inhibitory substances, used in the treatment of diabetes. At the same time, the medicine is recommended by the specialty commission in the endocrinology sector of the Health Ministry and is advised for the first-line treatment of people who concomitantly have type-II diabetes and heart failure.
According to estimations by the National Health Insurances Company (CNAM), about 10,000 patients with chronic diseases will benefit from dapagliflozinum, for the compensation of which 40 million lei (2 million euros) is to be annually allocated.
At the same time, the council for compensated medicines, at a meeting on October 21, informed that it had finished the assessment of files on the inclusion of another 11 international common denominations of preparations in the list of compensated medicines: five preparations for various types of cancer and six ones advised in the treatment of such diseases as schizophrenia, epilepsy, bronchial asthma, chronic obstructive bronchopneumopathy, angina pectoris and high blood pressure. (Moldpres/Business World Magazine)